EP2498790A1 - Souche de bifidobaterium - Google Patents

Souche de bifidobaterium

Info

Publication number
EP2498790A1
EP2498790A1 EP10779341A EP10779341A EP2498790A1 EP 2498790 A1 EP2498790 A1 EP 2498790A1 EP 10779341 A EP10779341 A EP 10779341A EP 10779341 A EP10779341 A EP 10779341A EP 2498790 A1 EP2498790 A1 EP 2498790A1
Authority
EP
European Patent Office
Prior art keywords
foodstuff
formulation
cells
strain
bifidobacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10779341A
Other languages
German (de)
English (en)
Inventor
Liam O'mahony
Barry Kiely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PrecisionBiotics Group Ltd
Iams Europe BV
Original Assignee
Alimentary Health Ltd
Iams Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/616,752 external-priority patent/US9771624B2/en
Application filed by Alimentary Health Ltd, Iams Co filed Critical Alimentary Health Ltd
Priority to EP14180970.7A priority Critical patent/EP2823822B1/fr
Publication of EP2498790A1 publication Critical patent/EP2498790A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/48—Moist feed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the invention relates to a Bifidobacterium strain and its use as a probiotic bacteria in particular as an immunomodulatory biotherapeutic agent.
  • the defense mechanisms to protect the human gastrointestinal tract from colonization by intestinal bacteria are highly complex and involve both immunological and non-immunological aspects (1).
  • Innate defense mechanisms include the low pH of the stomach, bile salts, peristalsis, mucin layers and anti-microbial compounds such as lysozyme (2).
  • Immunological mechanisms include specialized lymphoid aggregates, underlying M cells, called peyers patches which are distributed throughout the small intestine and colon (3). Luminal antigens presented at these sites result in stimulation of appropriate T and B cell subsets with establishment of cytokine networks and secretion of antibodies into the gastrointestinal tract (4).
  • antigen presentation may occur via epithelial cells to intraepithelial lymphocytes and to the underlying lamina limba immune cells (5). Therefore, the host invests substantially in immunological defense of the gastrointestinal tract.
  • the gastrointestinal mucosa is the largest surface at which the host interacts with the external environment, specific control mechanisms must be in place to regulate immune responsiveness to the 100 tons of food which is handled by the gastrointestinal tract over an average lifetime.
  • the gut is colonized by over 500 species of bacteria numbering 10 -10 /g in the colon.
  • these control mechanisms must be capable of distinguishing non-pathogenic adherent bacteria from invasive pathogens, which would cause significant damage to the host.
  • the intestinal flora contributes to defense of the host by competing with newly ingested potentially pathogenic micro-organisms.
  • probiotic bacteria are more effective when derived from the species, or closely related species, intended to be treated. Therefore, there is a need for probiotic strains derived from companion animals to be used for companion animals that are different to those derived from humans.
  • WO 01/90311 discloses probiotic micro-organisms isolated from faecal samples obtained from cats having probiotic activity. However, these bacteria were obtained from faecal samples, and may not form part of the natural intestinal microflora present in the upper portion of the GI tract.
  • the Bifidobacterium strain may be in the form of viable cells, the Bifidobacterium strain may be in the form of non-viable cells.
  • the Bifidobacterium may be isolated from colonic biopsy tissue from a feline subject.
  • the Bifidobacterium strain may be significantly immunomodulatory following oral consumption.
  • the invention also provides a formulation which comprises a Bifidobacterium strain as described herein.
  • the formulation may further comprise a probiotic material.
  • the formulation may further comprise a prebiotic material.
  • the formulation may further comprise an ingestable carrier.
  • the ingestible carrier may be a pharmaceutically acceptable carrier such as a capsule, tablet or powder.
  • the ingestible carrier may be a food product such as an oil suspension, a milk based suspension, cheese, a cocoa butter based composition, a gravy and/or a yoghurt based composition.
  • the invention further provides a foodstuff which comprises a Bifidobacterium strain or a formulation as described herein.
  • the foodstuff may be a dry foodstuff.
  • the foodstuff may be a wet foodstuff.
  • the foodstuff may further comprise a probiotic material.
  • the foodstuff may further comprise a prebiotic material.
  • the foodstuff may be a companion animal food.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use as a medicament.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use in the prophylaxis and/or treatment of undesirable inflammatory activity.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use in the prophylaxis and/or treatment of undesirable gastrointestinal inflammatory activity.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use in the prophylaxis and/or treatment of auto-immune disorders due to undesirable inflammatory activity.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use in the prophylaxis and/or treatment of diarrhoeal disease due to undesirable inflammatory activity.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use in the regulation of or improvement of the immune system of companion animals.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use in the prophylaxis and/or treatment of autoimmune disease in companion animals.
  • the invention also provides a Bifidobacterium strain, or a formulation, or a foodstuff as described herein for use in the prophylaxis and/or treatment of inflammation in companion animals.
  • the strain may be obtainable by isolation from resected and washed feline gastrointestinal tract.
  • the mutant may be a genetically modified mutant.
  • the variant may be a naturally occurring variant of Bifidobacterium.
  • the strain may be a probiotic. It may be in the form of a biologically pure culture.
  • Bifidobacterium strains may be in the form of viable cells. Alternatively Bifidobacterium strains may be in the form of non-viable cells.
  • probiotic bacteria may be in the form of viable cells. However, it may also be extended to non-viable cells such as killed cultures or compositions containing beneficial factors expressed by the probiotic bacteria. This may include thermally killed micro-organisms or microorganisms killed by exposure to altered pH or subjection to pressure. With non-viable cells product preparation may be simpler, cells may be incorporated easily into pharmaceuticals and storage requirements are much less limited than viable cells. Lactobacillus casei YIT 9018 offers an example of the effective use of heat killed cells as a method for the treatment and/or prevention of tumour growth as described in US Patent No. US4347240.
  • compositions comprising the lactic acid bacteria.
  • the formulation which comprises the Bifidobacterium strain described herein, the formulation may include another probiotic material,the formulation may include a prebiotic material.
  • Bifidobacterium are commensal microorganisms. They have been isolated from the microbial flora within the human gastrointestinal tract. The immune system within the gastrointestinal tract cannot have a pronounced reaction to members of this flora, as the resulting inflammatory activity would also destroy host cells and tissue function. Therefore, some mechanism(s) exist whereby the immune system can recognize commensal non-pathogenic members of the gastrointestinal flora as being different to pathogenic organisms. This ensures that damage to host tissues is restricted and a defensive barrier is still maintained.
  • mutant, variant and genetically modified mutant include a strain of Bifidobacteria whose genetic and/or phenotypic properties are altered compared to the parent strain.
  • Naturally occurring variant of Bifidobacterium longum includes the spontaneous alterations of targeted properties selectively isolated.
  • Deliberate alteration of parent strain properties is accomplished by conventional (in vitro) genetic manipulation technologies, such as gene disruption, conjugative transfer, etc.
  • Genetic modification includes introduction of exogenous and/or endogenous DNA sequences into the genome of a Bifidobacteria strain, for example by insertion into the genome of the bacterial strain by vectors, including plasmid DNA, or bacteriophages.
  • Natural or induced mutations include at least single base alterations such as deletion, insertion, transversion or other DNA modifications which may result in alteration of the amino acid sequence encoded by the DNA sequence.
  • mutant, variant and genetically modified mutant also include a strain of Bifidobacteria that has undergone genetic alterations that accumulate in a genome at a rate which is consistent in nature for all micro-organisms and/or genetic alterations which occur through spontaneous mutation and/or acquisition of genes and/or loss of genes which is not achieved by deliberate (in vitro) manipulation of the genome but is achieved through the natural selection of variants and/or mutants that provide a selective advantage to support the survival of the bacterium when exposed to environmental pressures such as antibiotics.
  • a mutant can be created by the deliberate (in vitro) insertion of specific genes into the genome which do not fundamentally alter the biochemical functionality of the organism but whose products can be used for identification or selection of the bacterium, for example antibiotic resistance.
  • mutant or variant strains of Bifidobacteria can be identified by DNA sequence homology analysis with the parent strain. Strains of Bifidobacteria having a close sequence identity with the parent strain are considered to be mutant or variant strains. A Bifidobacteria strain with a sequence identity (homology) of 96% or more, such as 97% or more, or 98% or more, or 99% or more with the parent DNA sequence may be considered to be a mutant or variant. Sequence homology may be determined using on-line homology algorithm "BLAST" program, publicly available at http://www.ncbi.nlm.nih,gov/BLAST/.
  • Mutants of the parent strain also include derived Bifidobacteria strains having at least 85% sequence homology, such as at least 90% sequence homology, or at least 95% sequence homology to the 16s - 23 s intergenic spacer polynucleotide sequence of the parent strain. These mutants may further comprise DNA mutations in other DNA sequences in the bacterial genome.
  • Fig. 1 is a photograph of B. longum AH121A grown on a Congo Red Agar plate
  • Fig. 2 is a bar chart illustrating the IL-10:IL-12p70 ratio for PBMCs stimulated with Bifidobacterium longum strain 121A (Bifidobacterium 121A);
  • Fig 3 is a plot illustrating the survival of strain 121 A in a low pH environment. Strains were challenged at pH2.5 for 6 hours and their survival assessed using plate counts;
  • Figs 4 to 6 are plots of cytokine secretions from in vitro cultured peripheral blood mononuclear cells (PBMCs);
  • Fig. 7 A to E are line graphs showing the induction profile of IL-10 in PBMC after in vitro stimulation with increasing concentrations of 121 A and Bif 35624;
  • Fig. 8 A to D are line graphs showing the induction profile of IL- ⁇ in PBMC after in vitro stimulation with increasing concentrations of 121 A and Bif 35624;
  • Fig. 9 A to D are line graphs showing the induction profile of IL-6 in PBMC after in vitro stimulation with increasing concentrations of 121 A and Bif 35624;
  • Fig. 10 A to D are line graphs showing the induction profile of IL-8 in PBMC after in vitro stimulation with increasing concentrations of 121 A and Bif. 35624;
  • Fig. 11 A to D are line graphs showing the induction profile of IL-12 p70 in PBMC after in vitro stimulation with increasing concentrations of 121 A and Bif. 35624;
  • Fig. 12 A to E are line graphs showing the induction profile of TNF-a in PMBC after in vitro stimulation with increasing concentrations of 121 A and Bif. 35624;
  • Fig. 13 A to C are line graphs showing the induction profile of IFN- ⁇ in PMBC after in vitro stimulation with increasing concentrations of 121 A and Bif. 35624;
  • Fig. 14 A to D are line graphs showing the inductions profile of G-CSF in PBMC after in vitro stimulation with increasing concentrations of 121 A and Bif. 35624;
  • Fig. 15 is a bar chart showing the effect of 121 A on the secretion of IL-10 and IL-12 p70 by human myeloid-type dendritic cells;
  • Fig. 16 is a bar chart showing the effect of 121 A on human naive CD4 Tcells.
  • Bifidobacterium longum strain AH121A was made at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA, Scotland, UK on November 5, 2009 and accorded the accession number NCIMB 41675.
  • a deposit of Bifidobacterium longum strain UCC 35624 was made at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA, Scotland, UK on January 13, 1999, and accorded the accession number NCIMB 41003.
  • the Bifidobacterium longum may be a genetically modified mutant or it may be a naturally occurring variant thereof.
  • the Bifidobacterium longum is in the form of viable cells.
  • the Bifidobacterium longum may be in the form of non- viable cells.
  • “companion animal” means a domestic animal.
  • “companion animal” means a domestic feline (cat), canine (dog), rabbit, ferret, horse, cow, or the like. More preferably, “companion animal” means a domestic feline. Lactic Acid Bifidobacteria Strains
  • the first aspect of the present invention comprises a strain of lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline gastrointestinal tract having probiotic activity in animals.
  • Probiotics are microorganisms, either viable or dead, processed compositions of micro-organisms, their constituents such as proteins or carbohydrates, or purified fractions of bacterial ferments that beneficially affect a host.
  • the general use of probiotic bacteria is in the form of viable cells. However, it can be extended to non- viable cells such as killed cultures or compositions containing beneficial factors expressed by the probiotic bacteria. This may include thermally killed micro-organisms, or micro-organisms killed by exposure to altered pH or subjected to pressure.
  • probiotics is further intended to include the metabolites generated by the micro-organisms of the present invention during fermentation, if they are not separately indicated. These metabolites may be released to the medium of fermentation, or they may be stored within the micro-organism.
  • probiotic also includes bacteria, bacterial homogenates, bacterial proteins, bacterial extracts, bacterial ferment supernatants, and mixtures thereof, which perform beneficial functions to the host animal when given at a therapeutic dose.
  • lactic acid bacteria of the genus Bifidobacteria obtainable by isolation directly from resected and washed GI tract of mammals are adherent to the GI tract following feeding of viable bacterial cells, and are also significantly immunomodulatory when fed to animals in viable, non-viable or fractionated form.
  • Bifidobacteria obtainable by isolation from resected and washed GI tract closely associate with the gut mucosal tissues. Without further being bound by theory, this is believed to result in the probiotic Bifidobacteria of the present invention generating alternative host responses that result in its probiotic action.
  • probiotic bacteria obtainable by isolation from resected and washed GI tract can modulate the host's immune system via direct interaction with the mucosal epithelium, and the host's immune cells.
  • This immunomodulation in conjunction with the traditional mechanism of action associated with probiotic bacteria, i.e. the prevention of pathogen adherence to the gut by occlusion and competition for nutrients, results in the Bifidobacteria of the present invention being highly efficacious as a probiotic organism.
  • the Bifidobacterium of the present invention obtainable by isolation from resected and washed feline GI tract, has in vitro anti-microbial activity against a number of pathogenic bacterial strains/species. Without being bound by theory, it is believed that this in vitro anti-microbial activity is indicative of potential probiotic activity in vivo in animals, preferably companion animals such as felines.
  • the lactic acid bacteria of the present invention preferably have in vitro anti-microbial activity against Salmonella typhimurium, Listeria monocytogenes, Listeria innocua or Eschericia coli, more preferably a mixture of these strains, more preferably still, all of these strains.
  • the anti -microbial activity of the lactic acid bacteria of the present invention may be the result of a number of different actions by the lactic acid bacteria herein. It has previously been suggested in the art that several strains of bacteria isolated from faecal samples exert their probiotic effect in the GI tract following oral consumption by preventing the attachment of pathogenic organisms to the gut mucosa by occlusion. This requires oral consumption of "live" or viable bacterial cells in order for a colony of bacteria to be established in the gut.
  • the Bifidobacteria of the present invention obtainable by isolation from resected and washed feline GI tract, whilst exerting some probiotic effect due to occlusion if given in a viable form, may deliver a substantial probiotic effect in either the viable or non-viable form due to the production during fermentation in vitro of a substance or substances that either inhibit the growth of or kill pathogenic microorganisms, and/or alter the host animal's immune competence.
  • This form of probiotic activity is desirable, as the bacteria of the present invention can be given as either viable or non-viable cultures or purified fermentation products and still deliver a beneficial therapeutic effect to the host animal.
  • the lactic acid bacteria of the present invention are able to maintain viability following transit through the GI tract. This is desirable in order for live cultures of the bacteria to be taken orally, and for colonisation to occur in the intestines and bowel following transit through the oesophagus and stomach. Colonisation of the intestine and bowel by the lactic acid bacteria of the present invention is desirable for long-term probiotic benefits to be delivered to the host. Oral dosing of non-viable cells or purified isolates thereof induces temporary benefits, but as the bacteria are not viable, they are not able to grow, and continuously deliver a probiotic effect in situ. As a result this may require the host to be dosed regularly in order to maintain the health benefits.
  • the lactic acid bacteria of the present invention maintain viability after suspension in a media having a pH of 2.5 for 1 hour.
  • “maintain viability” means that at least 25% of the bacteria initially suspended in the test media are viable using the plate count method known to those skilled in the art.
  • “maintain viability” means that at least 50% of the bacteria initially suspended are viable. It is desirable for the lactic acid bacteria of the present invention to maintain viability following exposure to low pH as this mimics the exposure to gastric juices in the stomach and upper intestine in vivo following oral consumption in animals.
  • the strain of lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline gastrointestinal tract can be used to deliver probiotic benefit following oral consumption in animals, preferably companion animals or humans. This probiotic benefit generally maintains and improves the overall health of the animal.
  • Non-limiting elements of animal health and physiology that benefit, either in therapeutically relieving the symptoms of, or disease prevention by prophylaxis include inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly those of the gastrointestinal and immune systems), diarrhoeal disease, antibiotic associated diarrhoea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer's disease, amyloidosis, rheumatoid arthritis, arthritis, joint mobility, diabetes mellitus, insulin resistance, bacterial infections, viral infections, fungal infections, periodontal disease, urogenital disease, surgical associated trauma, surgical- induced metastatic disease, sepsis, weight loss, weight gain, excessive adipose tissue accumulation, anorexia, fever control, cachexia, wound healing, ulcers, gut barrier infection, allergy, asthma, respiratory disorders, circulatory disorders, coronary heart disease, anaemia, disorders of the blood coagulation system, renal disease, disorders of the central nervous system,
  • inflammatory disorders including autoimmune disease and inflammation may be detected and monitored using in vivo immune function tests such as lymphocyte blastogenesis, natural killer cell activity, antibody response to vaccines, delayed-type hypersensitivity, and mixtures thereof.
  • in vivo immune function tests such as lymphocyte blastogenesis, natural killer cell activity, antibody response to vaccines, delayed-type hypersensitivity, and mixtures thereof.
  • Lymphocyte blastogenesis This assay measures the proliferative response in vitro of lymphocytes isolated from fresh whole blood of test and control animals to various mitogens and is a measure of overall T- and B-cell function. Briefly, peripheral blood mononucleocytes (PBMC) are isolated from whole blood by Ficoll-Hypaque density centrifugation methods known to those skilled in the art. The isolated PBMCs are washed twice in RPMI 1640 cell media supplemented with HEPES, L-glutamine and penicillin/streptomycin. The washed cells are resuspended in RPMI 1640, counted, and the cell density adjusted appropriately.
  • PBMC peripheral blood mononucleocytes
  • the 2xl0 5 cells are exposed to a range of concentrations (0 ⁇ / ⁇ to ⁇ ) of various mitogens, some examples of which include pokeweed mitogen (Gibco), phytohaemagglutinin (Gibco) and conconavalin A (Sigma) in triplicate for 72 hours at 37°C and 5% C0 2 with 10% foetal bovine serum (Sigma). At 54 hours the cells are pulsed with ⁇ H-thymidine, and the cells harvested and scintillation counts read on a TopCount NXT at 72 hours.
  • Natural killer cell activity As described in US 6,310,090, this assay measures the in vitro effector activity of natural killer cells isolated from fresh whole blood of test and control animals.
  • Natural killer cells are a component of the innate immune function of a mammal. Feline thyroid adenocarcinoma cells were used as target cells in assessing N cell cytotoxic activity. This cell line was previously shown to be susceptible to killing by feline NK cell. Target cells were cultured in a T75 flask with 20 niL minimum essential medium (MEM; Sigma Chem. Co., St. Louis, Mo.) supplemented with 10% fetal calf serum (FCS), 100 U/mL of penicillin and 100 ⁇ g mL of streptomycin.
  • MEM minimum essential medium
  • FCS fetal calf serum
  • target cells When confluent, target cells were trypsinized, washed 3 times and resuspended to 5x10 5 cells/mL in complete medium (RPMI- 1640+ 10% FCS+100 U/mL of penicillin+100 ⁇ g/mL of streptomycin). Triplicate ⁇ aliquots of the target cells were pipetted into 96-well U- bottom plates (Costar, Cambridge, Mass.) and incubated for 8 hours to allow cell adherence. Lymphocytes (effector cells; ⁇ ) isolated by Ficoll- Hypaque separation (as described above) were then added to the target cells to provide an effector/target cell (E: T) ratio of 10: 1.
  • E effector/target cell
  • Antibody response to vaccines The test subjects are given an array (up to 5) of vaccines after at least 12 weeks of probiotic or control feeding.
  • the vaccines may be a mixture of novel and redundant vaccines.
  • Non-limiting examples of vaccine arrays that may be used include mixtures of vaccines prepared by Fort Dodge Animal Health.
  • Non-limiting examples of vaccines suitable for use herein include Feline distemper, adenovirus, coronavirus, parainfluenza, and parvovirus.
  • the test subject's vaccine history will determine the vaccines to be used.
  • the specific antibodies to the vaccines given are measured in blood for 3 weeks and the length and strength of response in control and probiotic feeding groups compared.
  • Delayed-type hypersensitivity An in vivo, non- invasive method of assessing immune system status.
  • This test comprises an intradermal injection of the polyclonal mitogen Phytohemmaglutinin (PHA) in combination with sheep red blood cells a multivalent vaccine, histamine ( ⁇ , of 0.0275 g/L Histamine Phosphate; Greer, Lenoir, NC) or PBS ( ⁇ of Phosphate Buffered Saline, 8.5 g/L; Sigma).
  • PHA polyclonal mitogen Phytohemmaglutinin
  • the immune response to the antigen is recorded as skinfold thickness using calipers at time intervals of 0, 24, 48 and 72 hours post- injection. An increase in skinfold thickness is indicative of a greater hypersensitivity response that should be decreased by treatment with the bacteria of the present invention.
  • ameliorating the effects of age may be determined using dual x-ray absorptometry or CT scan for measuring body composition, including body fat mass, fat- free mass and bone mineral content.
  • this method may be used to determine anatomy changes such as weight loss or bone density in subjects following infection.
  • the Bifidobacteria of the present invention may also be used in a method for reducing stress levels in companion animals.
  • Concentrations of blood stress hormones including epinephrine, norepinephrine, dopamine, Cortisol, C-reactive protein and other acute phase proteins may be measured to determine stress levels and their reduction or maintenance. These hormones are recognized biomarkers of stress and can be readily measured using techniques known to those skilled in the art. Additionally, direct measure of adrenal size as an in vivo marker of activity of the hypothalamus-pituitary-adrenal axis may be measured by CT imaging.
  • maintenance or improvement of the health of the skin and/or coat system of companion animals, including atopic disease of the skin may be measured using skin and coat assessments conducted by two trained individuals.
  • criteria examined during such assessments include: a) Shedding index: A shedding index is assigned to each test subject by collecting hair produced during a standardized brushing session. The hair is retained and weighed, and control and test subjects compared, b) Subjective skin/coat evaluations: Trained panelists subjectively evaluate skin and coat condition by assessing shedding, dander, shine, uniformity, softness and density, c) Skin functional assessment: The barrier function of the skin may be assessed by wiping the skin surface with an acetone-soaked gauze.
  • TEWL transepidermal water loss
  • redness (erythema) scores are obtained using the previously described camera and lighting system.
  • TEWL readings and redness scores are obtained immediately before and after disruption, and at five and 24-hour endpoints to assess the protective and healing properties of skin.
  • the treatment of gastrointestinal infection in companion animals may comprise improving microbial ecology of companion animals. Improving the microbial ecology of companion animals preferably comprises reducing the levels of pathogenic bacteria in the faeces of companion animals.
  • the levels of pathogenic bacteria present in the faeces of companion animals may be enumerated using the standard plate count method known to those skilled in the art. More preferably, the pathogenic bacteria are selected from the group consisting of Clostridia, Escherichia, Salmonella, bacteriodes and mixtures thereof. Non-limiting examples of suitable strains of pathogenic bacteria include C. perfringens, C. difficile, Eschericia coli, Salmonella typhimurium and mixtures thereof.
  • the method of use of the bacteria of the present invention may also include the treatment, either prophylactic or therapeutic of the urinary tract of mammals, preferably companion animals.
  • Non- limiting examples of urinary tract treatment include treatment or prevention of urinary tract infections, treatment or prevention of kidney disease, including urinary tract stones, treatment or prevention of bladder infections and the like.
  • the Bifidobacteria bacteria of the present invention are useful in preventing these ailments as a result of their ability to degrade oxalic acid, as demonstrated in vitro.
  • Oxalic acid is a by-product of urinary metabolism that can form insoluble precipitates that result in kidney, bladder and other urinary tract infections.
  • the bacteria of the present invention may treat and prevent infections and other ailments of the urinary tract.
  • Oxalic acid degradation may be measured in vitro using the Oxalic acid test kit cat # 755699 commercially available from Boehringer Mannheirn/R-Biopharm.
  • the Bifidobacteria of the present invention may be used in a method for improving or maintaining the health of companion animals comprising improving fibre digestion. Improving fibre digestion is desirable as it promotes the growth of said probiotic bacteria, as well as beneficial endogenous microflora, which aid in the suppression of some potentially pathogenic bacteria. In addition, a decrease in the amount of toxic metabolites and detrimental enzymes that result from colonic fermentation has been documented in humans (6). Fibre digestion may be determined using the method described in Vickers et al. (7), with the exception that instead of inoculating using diluted fecal samples each experiment used pure cultures of the bacterial strains of interest.
  • the feline probiotic strains of the present invention may be used to reduce the odor of the feces and urine and concomitantly in the litterbox by reducing the production of compounds in the feces and urine that cause odor.
  • odor- causing compounds include ammonia, indoles, phenols, amines, branched chain fatty acids, and volatile sulphur-containing compounds.
  • the method of use of the lactic acid bacteria of the present invention typically involves oral consumption by the animal.
  • Oral consumption may take place as part of the normal dietary intake, or as a supplement thereto.
  • the oral consumption typically occurs at least once a month, preferably at least once a week, more preferably at least once per day.
  • the lactic acid bacteria of the present invention may be given to the companion animal in a therapeutically effective amount to maintain or improve the health of the animal, preferably a companion animal.
  • the term "therapeutically effective amount” with reference to the lactic acid bacteria means that amount of the bacteria sufficient to provide the desired effect or benefit to a host animal in need of treatment, yet low enough to avoid adverse effects such as toxicity, irritation, or allergic response, commensurate with a reasonable benefit/risk ratio when used in the manner of the present invention.
  • the specific "therapeutically effective amount” will vary with such factors as the particular condition being treated, the physical condition of the user, the duration of the treatment, the nature of concurrent therapy (if any), the specific dosage form to be used, the carrier employed, the solubility of the dose form, and the particular dosing regimen.
  • the lactic acid bacteria are given to the companion animal at a dose of from 1.OE+04 to 1.0E+14 CFU per day, more preferably from 1.0E+06 to 1.0E+12 CFU per day.
  • the composition preferably may contain at least 0.001% of from 1. OE+04 to 1.0E+12 CFU/g of the lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline GI tract.
  • the lactic acid bacteria can be given to the animal in either viable form, or as killed cells, or distillates, isolates or other fractions of the fermentation products of the lactic acid bacteria of the present invention, or any mixture thereof.
  • the lactic acid bacteria, or a purified or isolated fraction thereof are used to prepare a composition intended to maintain or improve the health of an animal.
  • the composition may be part of the normal dietary intake, or a supplement.
  • the composition may be in the form of a dried animal food such as biscuits or kibbles, a processed grain feed, a wet animal food, yoghurts, gravies, chews, treats and the like.
  • compositions may comprise further components.
  • Other components are beneficial for inclusion in the compositions used herein, but are optional for purposes of the invention.
  • food compositions are preferably nutritionally balanced.
  • the food compositions may comprise, on a dry matter basis, from about 20% to about 50% crude protein, preferably from about 22% to about 40% crude protein, by weight of the food composition.
  • the crude protein material may comprise any material having a protein content of at least about 15% by weight, non-limiting examples of which include vegetable proteins such as soybean, cotton seed, and peanut, animal proteins such as casein, albumin, and meat tissue.
  • meat tissue useful herein include fresh meat, and dried or rendered meals such as fish meal, poultry meal, meat meal, bone , meal and the like.
  • suitable crude protein sources include wheat gluten or corn gluten, and proteins extracted from microbial sources such as yeast.
  • the food compositions may comprise, on a dry matter basis, from about 5% to about 35% fat, preferably from about 10% to about 30% fat, by weight of the food composition.
  • food compositions comprising the lactic acid bacteria of the present invention may also comprise from about 4% to about 25% total dietary fibre.
  • the compositions may also comprise a multiple starch source as described in W099/51 108.
  • the compositions of the present invention may further comprise a source of carbohydrate. Grains or cereals such as rice, corn, milo, sorghum, barley, alfalfa, wheat, and the like are illustrative sources.
  • the compositions may also contain other materials such as dried whey and other dairy by products.
  • compositions comprising the bacteria of the present invention may also comprise a prebiotic.
  • prebiotic includes substances or compounds that are fermented by the intestinal flora of the companion animal and hence promote the growth or development of lactic acid bacteria in the gastro-intestinal tract of the companion animal at the expense of pathogenic bacteria. The result of this fermentation is a release of fatty acids, in particular short-chain fatty acids in the colon. This has the effect of reducing the pH value in the colon.
  • suitable prebiotics include oligosaccharides, such as inulin and its hydrolysis products commonly known as fructooligosaccharides, galacto- oligosaccarides, xylo-oligosaccharides or oligo derivatives of starch.
  • the prebiotics may be provided in any suitable form.
  • the prebiotic may be provided in the form of plant material which contains the fiber. Suitable plant materials include asparagus, artichokes, onions, wheat or chicory, or residues of these plant materials.
  • the prebiotic fiber may be provided as an inulin extract, for example extracts from chicory are suitable. Suitable inulin extracts may be obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark "Raftiline".
  • the inulin may be provided in the form of Raftiline (g) ST which is a fine white powder which contains about 90 to about 94% by weight of inulin, up to about 4% by weight of glucose and fructose, and about 4 to 9% by weight of sucrose.
  • the fiber may be in the form of a fructooligosaccharide such as obtained from Orafti SA of Tirlemont 3300, Belgium under the trade mark "Raftilose”.
  • the inulin may be provided in the form of Raftilose (g) P95.
  • the fructooligosaccharides may be obtained by hydrolyzing inulin, by enzymatic methods, or by using micro-organisms.
  • a suitable process is extrusion cooking, although baking and other suitable processes may be used.
  • the dried companion animal food is usually provided in the form of a kibble.
  • the prebiotic may be admixed with the other ingredients of the dried companion animal food prior to processing.
  • a suitable process is described in European patent application No 0850569. If a probiotic micro-organism is used, the organism is best coated onto or filled into the dried companion animal food.
  • a suitable process is described in European patent publication Number EP 0 862 863.
  • Typical wet food compositions may comprise from about 5% to about 15% protein, from about 1% to about 10% fat, and from about 1% to about 7% fibre.
  • Non-limiting ingredients that may be used in wet food compositions include chicken, turkey, beef, whitefish, chicken broth, turkey broth, beef broth, chicken liver, brewers rice, corn grits, fish meal, egg, beet pulp, chloride, flax meal, lamb, beef byproducts, chicken by-products and mixtures thereof.
  • supplement compositions such as biscuits, chews, and other treats may comprise, on a dry matter basis, from about 20% to about 60% protein, or from about 22% to about 40% protein, by weight of the supplement composition.
  • the supplement compositions may comprise, on a dry matter basis, from about 5% to about 35% fat, or from about 10% to about 30% fat, by weight of the supplement composition.
  • Food and supplement compositions intended for use by felines or felines are commonly known in the art.
  • the companion animal foods may contain other active agents such as long chain fatty acids and zinc.
  • Suitable long chain fatty acids include alpha-linoleic acid, gamma Hnolenic acid, linoleic acid, eicosapentanoic acid, and docosahexanoic acid.
  • Fish oils are a suitable source of eicosapentanoic acids and docosahexanoic acid.
  • Borage oil, blackcurrent seed oil and evening primrose oil are suitable sources of gamma Hnolenic acid.
  • Safflower oils, sunflower oils, corn oils and soy bean oils are suitable sources of linoleic acid. These oils may also be used in the coating substrates referred to above.
  • Zinc may be provided in various suitable forms, for example as zinc sulfate or zinc oxide. Further, many ingredients commonly used in companion animal foods are sources of fatty acids and zinc. It has been observed that the combination of chicory, as a source of prebiotic, with a linoleic-acid rich oil, such as soy bean oil, provides unexpected benefits, suggestive of a synergistic effect.
  • the composition preferably comprises at least 10% of a broth, or stock, non-limiting examples of which include vegetable beef, chicken or ham stock.
  • Typical gravy compositions may comprise from about 0.5% to about 5% crude protein, from about 2% to about 5% crude fat, and from about 1% to about 5% fibre.
  • Further non-limiting examples of supplements suitable for use herein include powders, oil suspensions, milk-based suspensions, cheeses, cocoa-butter-based compositions and pills or capsules.
  • suitable binding agents are required to maintain the pill in a solid, pressed form.
  • Non- limiting examples of suitable binding agents include the natural gums such as xanthan gum, pectins, lecithins, alginates and others known to those skilled in the art.
  • the composition is in the form of a capsule, the composition is preferably encapsulated using technologies known to those skilled in the art.
  • suitable encapsulation materials include polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), alginates, and gelatin.
  • Yoghurt-based compositions may comprise from about 1% to about 5% protein, from about 10% to about 20% carbohydrate, from about 1% to about 5% fibre, from about 1% to about 5% fat and from about 50% to about 90% liquid carrier such as milk.
  • Bifidobacterium longum strain AH121a was isolated from feline bowel tissue.
  • Feline intestinal samples were obtained from healthy cats presenting at the local veterinarians for owner initiated and approved euthanasia. All animals were healthy and disease-free. The colon, mid-colon, caecum and ileum of each cat were dissected in order to expose the mucosa.
  • IGS intergenic spacer
  • IGS R 5 ' -CTGGTGCC AAGGC ATCC A-3 ' (SEQ ID NO. 4) which resulted in the identification of SEQ ID NO. 2.
  • the cycling conditions were 94°C for 3 min (1 cycle), 94°C for 30 sec, 53°C for 30 sec, 72°C for 30 sec (28 cycles).
  • the PCR reaction contained 4 ⁇ (50ng) of DNA, PCR mix (XNAT2 kit), 0.4 ⁇ IGS L and R primer (MWG Biotech, Germany). The PCR reactions were performed on an Eppendorf thermocycler.
  • PCR products (10 ⁇ ) were run alongside a molecular weight marker (100 bp Ladder, Roche) on a 2 % agarose EtBr stained gel in TAE, to determine the IGS profile.
  • PCR products of Bifidobacterium (single band) were purified using the Promega Wizard PCR purification kit.
  • the purified PCR products were sequenced using the primer sequences (above) for the intergenic spacer region. Sequence data was then searched against the NCBI nucleotide database to determine the identity of the strain by nucleotide homology.
  • the resultant DNA sequence data was subjected to the NCBI standard nucleotide-to- nucleotide homology BLAST search engine (http://www.ncbi.nlm.nih.gov/BLAST/). The nearest match to the sequence was identified and then the sequences were aligned for comparison using DNASTAR MegAlign software.
  • the sequences (SEQ ID NO. 1 [IGS forward sequence] and SEQ ID NO. 2 [IGS reverse sequence]) obtained can be viewed in the sequence listing. Searching the NCIMB database revealed that AH121A has a unique IGS (SEQ ID NO. 1 [forward sequence] and SEQ ID NO. 2 [reverse sequence]) sequence with its closest sequence homology to a Bifidobacterium longum.
  • a Congo red agar screen was used to phenotypically screen for EPS expressing bacterial strains. Briefly, 10ml Modified Rogosa broth media (+ 0.05% cysteine) was inoculated aseptically with a freshly grown colony of the bacterial strain and incubated anaerobically at 37°C until turbid (about 16 to about 24 hours). The broth cultures were aseptically streaked onto Congo Red Agar plates and incubated anaerobically at 37°C for 48 hours. It is believed that EPS produced as a byproduct of the growth and/or metabolism of certain strains prevents the uptake of the Congo red stain resulting in a cream/white colony morphology. Stains that produce less EPS take up the Congo red stain easily, resulting in a pink/red colony morphology. Strains that do not produce an EPS stain red and look almost transparent in the red agar background.
  • feline bacterial isolate AHF121A To determine the resistance of feline bacterial isolate AHF121A to various concentrations of porcine bile and to assess the survival of feline bacterial isolate AHF121A at pH 2.5 for 6 hours and subsequent bile resistance using various concentrations of bile.
  • the test strain was AHF121A Bifidobacterium longum. Resistance to bile is examined using MRS/RCA agar plates supplemented with porcine bile (0.3, 0.5, 1.0, 2.0, 5.0, 7.5 and 10%). The survival of the strains at pH 2.5 is monitored at intervals of -5, 5, 30, 60, 120, 180 and 360 min using the plate count method. The bile resistance is examined after challenging the strains at pH 2.5 for 6h.
  • feline bile resistance The procedure for the determination of feline bile resistance is outlined below. An assessment of the survival rate of freeze dried bacteria in the presence of various concentrations of feline bile, ranging from 0.3 % to 10 %, was carried out.
  • Synthetic feline bile plates of various concentrations were prepared by making a 45% stock solution of synthetic bile, heat treating the bile stock at at 80°C for 10 min to kill any vegetative cells.
  • Bile plates were made fresh daily, but can be stored for up to one week.
  • the CFU/g of each freeze-dried test stain was quantified via the spread plating technique.
  • Test strains were spotted on porcine bile plates by resuspending 10 CFU/ml of freeze-dried strains into 10 ml sterile PBS, dividing the porcine bile plates into 1 ⁇ 4, and spoting 4 strains (10 ⁇ ) /plate.
  • the plates were dried on the bench for 30 min (or until the spot had dried into the agar) and incubated under under appropriate conditions.
  • Enumeration of freeze-dried powders was carried out using the spread plate technique.
  • the Media was acidified by adding 6 M HCl to 100 ml broth adjust to pH 2.5. The volume required to make adjustment was recorded and using sterile techniques the pH of 4 x 100 ml MRS broth (remaining broth) was adjusted using the same volume of acid.
  • the CFU/g of each freeze-dried test stain was quantified using the spread plate technique
  • Table 1 demonstrates the effect of feline bile on the growth of the strain.
  • the feline bacterial strain was able to tolerate ⁇ 2% feline bile concentrations
  • PBMCs Peripheral blood mononuclear cells
  • BD catalog 362761 BD Vacutainer CPT tubes
  • PBMCs were washed and resuspended in Dulbecco's Modified Eagle Medium- GlutamaxTM (Glutamax (Glutamine substitute) + pyruvate + 4.5 g/1 glucose (Gibco catalog 10569-010) 10% fetal bovine serum (Sigma catalog F4135), and 1% penicillin/streptomycin (Sigma catalog P0781).
  • Dulbecco's Modified Eagle Medium- GlutamaxTM Glutamax (Glutamine substitute) + pyruvate + 4.5 g/1 glucose (Gibco catalog 10569-010) 10% fetal bovine serum (Sigma catalog F4135), and 1% penicillin/streptomycin (Sigma catalog P0781).
  • PBMCs were incubated (2 x 10 5 cells per well) in flat-bottomed 96- well plates and 20 ⁇ , of a bacterial suspension (at a concentration of 1 x 10 7 CFU/mL ) was added. PBMCs were co- incubated with bacteria for 48 hours at 37°C / 5% C0 2 in an incubator. After the 2 day incubation period, the plates were centrifuged at 300 x g, and the supernatants were removed and stored frozen at -80°C until analysis.
  • Interleukin-10 (IL-10) and Interleukin-12p70 (IL-12p70) levels in the culture supernatants were quantified using a 96-well assay kit from Meso Scale Discovery (Gaithersburg, MD; catalog K15008B-1) Bacteria were prepared for co-culture experiments in two formats, (a) Freshly grown bacteria were grown in Difco MRS media and harvested just after entering into stationary phase. All cells were grown under anaerobic conditions at 37°C. (b) Bacteria were grown under anaerobic conditions at 37°C in Difco MRS media and harvested just after entering into stationary phase. Freeze dried powders were generated for each of these bacteria and stored at -80°C in pre- aliquoted lOOmg vials.
  • Fig. 2 illustrates the effect of strain 121A on IL-10:IL-12 induction. Both freshly grown and freeze-dried cultures exhibited a similar effect.
  • PBMCs Human peripheral blood mononuclear cells
  • IL-10 is a very important cytokine for controlling aberrant pro-inflammatory immune responses.
  • IL-10 knock-out animals develop colitis and gastrointestinal tumours while regulatory cells within the immune system secrete and utilize IL-10 in order to control potentially damaging immune responses.
  • enhanced secretion of this cytokine would be protective against inappropriate inflammatory activity and excessive immune responses to pathogens.
  • IL-10 secretion from in vitro cultured peripheral blood mononuclear cells was determined 48 hours after co-incubation with each bacterial strain. The strains induced IL-10 secretion with similar IL-10 levels being noted for AHF121A and 35624.(Figs 4 to 6).
  • Example 6 Bif. AH121a has immunomodulatory activity when co-incubated with human immune system cells in vitro, different to that of Bif. AH35624.
  • Bifidobacterium longum infantis strain UCC35624 (B624) and Bifidobacterium longum strain 121a is assayed using a PBMC cytokine induction assay.
  • Bacteria are prepared for co-culture experiments in the following formats. Bacteria are grown under anaerobic conditions at 37°C in Difco MRS Media and harvested just after entering into stationary phase. Freeze dried powders are generated for each of these bacteria and stored at -80°C in pre-aliquoted lOOmg vials. Immediately prior to their use, one aliquot of each strain is removed from the freezer and allowed to reach room temperature. Each strain is washed 3 times in 10ml ringers followed by centrifugation.
  • a fresh vial is used on each occasion. Direct microscopic counts are performed using a Petroff-Hausser counting chamber as per the manufacturer's instructions and washed cells normalized by cell number before addition to the PBMC assay. Bacteria (20 ⁇ in phosphate buffered saline (PBS)) are added to each well of PBMCs to give the total number of bacteria as indicated for each experiment.
  • PBS phosphate buffered saline
  • PBMC peripheral blood mononuclear cell
  • PBMCs Peripheral blood mononuclear cells
  • BD Vacutainer CPT tubes BD catalog 362761
  • PBMCs Peripheral blood mononuclear cells
  • BD catalog 362761 BD Vacutainer CPT tubes
  • PBMCs are washed and resuspended in Dulbecco's Modified Eagle Medium- Glutamax TM (Glutamax (Glutamine substitute) + pyruvate + 4.5 g/1 glucose (Gibco catalog 10569-010) 10% fetal bovine serum (Sigma catalog F4135), and 1% penicillin/streptomycin (Sigma catalog P0781).
  • PBMCs are incubated (2 x 10 5 cells per well) in flat-bottomed 96- well plates and 20 ⁇ of a bacterial suspension (with concentration ranges between 1 x 10 " CFU/mL) added. Up to 6 different amounts of bacteria are tested: 2.5E+08, 1.0E+08, 5.0E+07, 2.5E+07, 1.0E+07, and 1.0E+06. A no-bacteria control also is run. All assays are done in triplicate. After a 2-day incubation at 37°C, the plates were spun at 300 x g, and the supernatants were removed and stored frozen at -80°C until analysis.
  • PBMCs are co-incubated with bacteria for 48 hours at 37°C / 5% C0 2 in an incubator.
  • Cytokines in the culture supernatants are assayed using a 96-well assay kit from Meso Scale Discovery (Gaithersburg, MD; catalog K15008B-1).
  • Human Interleukin 1 beta (Il- ⁇ ), Human Interleukin 6 (Il- ⁇ ), Human Interleukin 8 (11-8) Human Interleukin 10 (11-10), Human Interleukin 12p70 (I112p70), Human Interferon-gamma (IFN- ⁇ ), Human Tumor Necrosis Factor alpha (TNFa) and Human G-CSF are quantitated and reported as picograms per millilitre (pg/mL). Each sample is assayed in 3-5 replicates (A to E). Results
  • Bifidobacterium longum infantis strain UCC35624 (B624) and Bifidobacterium longum strain 121a are assayed for immuno-modulation using a PBMC cytokine induction assay, to generate extended dose response curves with up to 6 different amounts of bacteria tested: 2.5E+08, 1.0E+08, 5.0E+07, 2.5E+07, 1.0E+07, and 1.0E+06.
  • Supernatants are assayed for a range of cytokines, including IL- ⁇ , -6, -8, -10 and -12, TNF-a, IFN- ⁇ and G-CSF. Cytokine measurement is represented as the average (+/- SEM) from up to 5 individual donors (A to E).
  • strain 121a exhibited a very similar pattern for the induction of most cytokines including IL-10, but quite a different pattern and increased production of IL-6 and IL-8.
  • IL-10 Incubation with 121a induces a dose-responsive increase in the anti-inflammatory cytokine IL-10 in PBMC after in vitro stimulation (Fig. 7). Induction of IL-10 is qualitatively and quantitatively similar to incubation with 35624. Maximal induction of IL-10 does not appear to be met with up to 1.0 x 10 9 bacteria per well.
  • IL- ⁇ Incubation with 121a induces a dose-responsive increase in the pro-inflammatory cytokine IL- ⁇ ⁇ in PBMC after in vitro stimulation (Fig. 8). Induction of IL- ⁇ is qualitatively and quantitatively similar to incubation with 35624. Maximal induction of IL- ⁇ ⁇ does not appear to be met with up to 1.0 x 10 9 bacteria per well.
  • IL-6 Incubation with 121a induces a dose-responsive increase in the cytokine IL-6 in PBMC after in vitro stimulation (Fig. 9). Quantitatively the pattern is different with 121a as compared with 35624; with higher levels of IL-6 measured with 121a especially at lower doses of bacteria per well.
  • IL-8 Incubation with 121a induces a dose-responsive increase in the cytokine IL-8 in PBMC after in vitro stimulation (Fig. 10). Quantitatively the pattern is different with 121a as compared with 35624; with higher levels of IL-8 measured with 121a across all doses of bacteria per well.
  • IL-12 Incubation with 121a induces a dose-responsive increase in the pro-inflammatory cytokine IL-12 in PBMC after in vitro stimulation (Fig. 1 1).
  • the pattern of modulation of IL-12 is bell- shaped with 121a and with 35624, rising to peak levels and then decreasing with higher bacterial concentrations. Quantitatively the pattern is somewhat variable for IL-12, but on balance similar with 121 a as compared with 35624.
  • TNF-a Incubation with 121a induces a dose-responsive increase in the pro-inflammatory cytokine TNF-a in PBMC after in vitro stimulation (Fig. 12).
  • TNF-a Induction of TNF-a is qualitatively and quantitatively similar to incubation with 35624 for 3 of 5 replicates, with higher levels of TNF-a found in 2 of 5 replicates (See C & E). Maximal induction of IL-10 appears to be met with up to 1.0 x 10 bacteria per well.
  • INF-y Incubation with 121a induces a dose-responsive increase in the pro-inflammatory cytokine INF- ⁇ in PBMC after in vitro stimulation (Fig. 13). Quantitatively the pattern is somewhat variable for INF- ⁇ , but on balance similar with 121a as compared with 35624.
  • G-CSF Incubation with 121a induces a dose-responsive increase in the cytokine G-CSF in PBMC after in vitro stimulation (Fig. 14). Induction of G-CSF is qualitatively and quantitatively similar to incubation with 35624.
  • the immune response is a tightly regulated process which normally results in protection from infection and tolerance of innocuous environmental antigens.
  • the activated immune response results in a chronic pro-inflammatory state characterized by activation of the innate immune response and expansion of polarized T cell subsets.
  • the treatment of inflammatory disease is focussed on the suppression of key inflammatory mediators or inflammatory cell populations.
  • these approaches only provide a temporary suppression of disease symptoms.
  • Successful long-term treatment or prevention can only be provided by enhancement of the regulatory cellular processes which protect against damaging proinflammatory responses.
  • Bifidobacterium AHF121A is a probiotic microbe that selectively stimulates IL-10 secretion from the innate immune system (i.e. dendritic cells) and induces polarization of Foxp-3 positive regulatory T cells in vitro.
  • IL-10 secretion and regulatory T cells are potent suppressors of aberrant inflammatory responses. Trpg cells
  • T reg T regulatory
  • T-cell-mediated diseases including allergy, asthmatic lung inflammation, autoimmune diseases and allograft rejection, by restoring immune tolerance to allergens, self antigens or alloantigens [8].
  • Multiple molecular mechanisms for T reg mediated immunosuppression have been described with secretion of IL-10 being of particular importance [9]. Absence or defective function of T reg cells has also been correlated with hyper IgE syndrome, hypereosinophilia and autoimmunity in humans, whereas their presence has been associated with immune tolerance [10].
  • allergen-specific IL-10 producing T regs are the dominant T-cell subset in healthy individuals [1 1, 12].
  • TRI cells allergen-specific IL-10 producing T regs
  • Repeated exposure of non-allergic healthy beekeepers to bee venom antigens during the bee keeping season represents a valuable in vivo model to ascertain mechanisms of immune tolerance to venom antigens [13].
  • venom antigen-specific THI and TH2 cells switch toward IL-10- secreting TRI cells. This occurs in parallel to the suppression of cutaneous late-phase responses to allergens and inhibition of allergen-specific THI and TH2 cells. The response is observed as long as venom exposure persists and returns to initial levels within 2 to 3 months after the end of the bee keeping season.
  • T reg function in vivo Various strategies, which are designed to enhance T reg function in vivo are currently under investigation. These include the adoptive transfer of inducible or constitutive T reg cells and their induction by specific adjuvants or immunomodulators. These approaches are attractive compared to conventional treatments, as the antigen-specific suppressor capacity of T reg cells does not result in general immunosuppression and may actually lead to long-lasting antigen-specific regulation in vivo. Moreover, individual patient-specific treatments are possible with limited side effects.
  • TNF- ⁇ tumor necrosis factor-a
  • T reg cells can be effective at suppressing ongoing disease, although those T reg cells do not necessarily need to recognize exactly the same autoantigen as the autoaggressive effector T cells [20].
  • Possibilities of adoptive transfer of T reg cells or small molecular compounds that induce T reg cells in the tissue are being investigated [19], but no double-blind, placebo-controlled studies have been reported so far.
  • allergen-SIT is the only antigen-specific approach that induces T reg cell production and activation in humans.
  • Allergen-SIT induces T reg and IL-10-secreting T l-like cells and treatment with glucocorticoids and ⁇ 2 adrenergic agonists seems to promote the number and activity of these cells [21-23].
  • the essential transcriptional elements regulating expression of the Foxp3 promoter have been recently reported and these will provide new targets for the development of novel therapeutics [24, 25].
  • microbes which are currently being examined include Bifidobacteria, Lactobacilli, non-pathogenic E. coli and Bacteroides strains [26-31].
  • the protective effects associated with these microbes are probably mediated by multiple mechanisms involving epithelial cells, dendritic cells and T cells.
  • a common feature of these microbes, which is being increasingly reported is their ability to induce T reg cells.
  • T reg cells are derived from the thymus but may also be induced in peripheral organs, including the gut mucosa [35, 36].
  • CD103+ dendritic cells within the mucosa are largely responsible for the conversion of T reg cells via TGF- ⁇ and retinoic acid dependent processes [37, 38].
  • the conversion is likely driven by gastrointestinal specific environmental factors associated with the presence of large numbers of commensal organisms. However, it is unlikely that all commensal microbes are equally effective at inducing T reg cells in vivo.
  • polysaccharide A derived from Bacteroides fragilis promotes an appropriate TH1/T h 2 balance in germ-free mice following presentation by mucosal dendritic cells and protects against colitis in an animal model via IL-10 secreting CD4 + T cells [29, 40].
  • the continued identification of new microbial compounds which induce tolerogenic dendritic cells and T reg activity will undoubtedly lead to novel therapeutic molecules for assessment in clinical studies.
  • CD14-specific antibody coated magnetic microbeads CD14-specific antibody coated magnetic microbeads (MiltentyiBiotec). The purity of isolated CD 14+ cell fraction was greater than 90% in all experiments.
  • iDCs immature DC
  • the purified CD 14+ cells were cultured for 5 days in the presence of IL-4 (R&D systems) and GM-CFS (R&D systems) to differentiate into myeloid dendritic cells. At day 6 the cells were left unstimulated (iDCs) or were stimulated with LPS (1 mg/mL) 5x105 MDDCs were stimulated with or bacterial cells for 24 hours.
  • PBMCs were isolated by centrifugation of buffy coats on Lymphoprep gradients.
  • CD4+ T cells were separated using negative selection affinity columns (R&D Systems), according to the manufacturer's instructions. After separation, the T cells were washed and resuspended in RPMI 1640culture medium supplemented with 10% heat- inactivated foetal bovine serum, 100 IU/mL penicillin, 100 ⁇ g/mL streptomycin, and 2 mmol/L L-glutamine.
  • Purified CD4+ Tcells (1 x 10 6 /mL) were stimulated by the combination of immobilized anti-CD3 (1 ⁇ g/mL) and soluble anti- CD28 (5 ⁇ g/mL) mAbs (Pharmingen).
  • CD4+ T cells were incubated with the above DCs. After 48 h of CD4+ T cells were permeabilised and stained for CD25 and Foxp-3. Cells were assessed using flow cytometry. The results show that AHF121A stimulated dendritic cells drive the polarisation and/or expansion of the regulatory T cell subset which expresses CD25 and Foxp-3.
  • cytokines released can have an impact on T cell polarization. Therefore, we analyzed the production of IL-12p70, and IL-10 by MoDCs after 24 h treatment with bacteria, as above. LPS was a strong inducer of all of the tested cytokines, while the AHF121 A elicited a differential cytokine release (Fig. 15). AHF121A induced lower levels of IL-10 when compared to LPS but did not induce a detectable level of IL-12p70. Thus AHF121A was displaying a reduced inflammatory potential
  • the difference in cytokine production reflects different T cell polarizing ability
  • Cytokine release by DCs is important to drive the polarization of T cells towards Thl, Th2, Thl 7 or T regulatory cells.
  • MDDCs generated by AHF121A have the potential to induce Foxp3+ Tregs.
  • DCs were incubated with AHF121A for 5 days and then cocultured with highly purified allogeneic naive CD4+ T cells.
  • the CD4+Foxp3+ Treg population was then analyzed by FACS. The results show that AHF121A stimulated dendritic cells drive the polarisation and /or expansion of the regulatory T cell subset which expresses CD25 and Foxp-3. (Fig.
  • AHF121A generated tolerogenic DCs, which, in turn, induced generation of CD4+Foxp3+ Tregs.
  • MDDCs cultured with AHF121A could convert CD4+CD25- T cells into CD4+CD25-Foxp3+ T cells .
  • AHF121A exerted potent immunomodulatory effects by up-regulating or potentiating the generation of Tregs by MDDCs in vitro.
  • the results present evidence of the generation of CD4+CD25-Foxp3+ Tregs in response to AHF121A in vitro, an effect that may be therapeutically useful for the modulation of inflammatory immune disorders in vivo.
  • T regulatory cells 32, 41, 42.
  • Bifidobacterium AH1206 was shown to mediate the potent activation of the T regulatory cells in 3 different animal models.
  • consumption of Bifidobacterium AH 1206 protected against eosinophil recruitment to the lung and blocked the induction of serum IgE.
  • T regulatory cells play an important role in regulating allergen-specific inflammatory responses (39).
  • Multiple studies in animal models indicate CD4 CD25 Foxp3 cells are recruited into both lungs and draining lymph nodes and can suppress allergen-induced airway eosinophillia, mucous hypersecretion and airway hyperresponsiveness (43-48).
  • Example 8 Example Compositions
  • the following are examples of dried kibble compositions comprising the probiotic Bifidobacteria of the present invention.
  • wet companion animal food compositions comprising the probiotic Bifidobacteria longum of the present invention.
  • yoghurt supplement compositions comprising the probiotic Bifidobacteria longum of the present invention.
  • Roncarolo MG Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nature Rev Immunol 2007;7:585-98.

Abstract

L'invention concerne une souche de Bifidobacterium AH121A qui est significativement immunomodulatrice après consommation orale. Ladite souche est utilisée comme agent biothérapeutique immunomodulateur.
EP10779341A 2009-11-11 2010-11-11 Souche de bifidobaterium Withdrawn EP2498790A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14180970.7A EP2823822B1 (fr) 2009-11-11 2010-11-11 Souche de bifidobacterium

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/616,752 US9771624B2 (en) 2008-11-11 2009-11-11 Bifidobacterium longum
IE20100290 2010-05-11
PCT/IE2010/000067 WO2011058536A1 (fr) 2009-11-11 2010-11-11 Souche de bifidobaterium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP14180970.7A Division EP2823822B1 (fr) 2009-11-11 2010-11-11 Souche de bifidobacterium

Publications (1)

Publication Number Publication Date
EP2498790A1 true EP2498790A1 (fr) 2012-09-19

Family

ID=43478228

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14180970.7A Not-in-force EP2823822B1 (fr) 2009-11-11 2010-11-11 Souche de bifidobacterium
EP10779341A Withdrawn EP2498790A1 (fr) 2009-11-11 2010-11-11 Souche de bifidobaterium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP14180970.7A Not-in-force EP2823822B1 (fr) 2009-11-11 2010-11-11 Souche de bifidobacterium

Country Status (11)

Country Link
EP (2) EP2823822B1 (fr)
JP (1) JP5600179B2 (fr)
CN (1) CN103037875B (fr)
AU (1) AU2010317423C1 (fr)
BR (1) BR112012010923B1 (fr)
CA (1) CA2779597C (fr)
ES (1) ES2610829T3 (fr)
MX (1) MX2012005449A (fr)
PL (1) PL2823822T3 (fr)
RU (1) RU2557310C2 (fr)
WO (1) WO2011058536A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011151941A1 (fr) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice
CN103124559B (zh) 2010-08-04 2017-03-29 托马斯·朱利叶斯·波洛迪 用于粪便菌群植入的组合物及其制备和使用方法以及递送该组合物的装置
CN108676774B (zh) 2011-12-01 2023-05-09 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
NZ737786A (en) 2015-05-22 2022-07-01 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2018071536A1 (fr) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions et procédés pour traiter la cholangite sclérosante primitive et des troubles associés
WO2018071537A1 (fr) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions et méthodes pour traiter la sclérose en plaques et des troubles associés
CN107334786B (zh) * 2016-12-29 2018-08-28 哈尔滨学院 双歧杆菌活菌胶囊及其在制备预防卵巢早衰药物中的应用
WO2018158309A1 (fr) 2017-02-28 2018-09-07 Alimentary Health Limited Bifidobacterium longum apte à moduler de manière bénéfique une réponse immunitaire à l'encontre d'une infection virale respiratoire
DK3532603T3 (da) * 2017-02-28 2020-12-07 Prec Group Limited Bifidobacterium longum til fordelagtig modulation af immunrespons på respiratorisk virusinfektion
WO2018187464A1 (fr) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions et méthodes pour traiter la diverticulite et des troubles associés
WO2018187467A1 (fr) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions et méthodes pour traiter la maladie de parkinson (pd) et des troubles associés
EP3630190B1 (fr) 2017-05-26 2024-02-21 Finch Therapeutics Holdings LLC Compositions lyophilisées comprenant des agents thérapeutiques à base de microbes fécaux et leurs procédés de fabrication et d'utilisation
WO2019032573A1 (fr) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions et procédés pour le maintien et la restauration d'une barrière intestinale saine
EP3745872B1 (fr) * 2018-01-29 2021-09-15 PrecisionBiotics Group Limited Association médicamenteuse destinée à la prophylaxie et au traitement du syndrome du côlon irritable
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US20220000948A1 (en) 2018-09-10 2022-01-06 Lactobio A/S Method for reducing the transfer of pathogenic microorganisms
CN113164527A (zh) 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
WO2020127637A1 (fr) 2018-12-21 2020-06-25 Lactobio Aps Composition topique comprenant des microorganismes viables
AU2019379234A1 (en) 2019-01-04 2021-07-29 Lactobio A/S Strains, composition and method of use
CA3140493A1 (fr) 2019-05-20 2020-11-26 Lactobio A/S Composition pour le traitement, l'amelioration ou la prophylaxie de l'acne
US20220233614A1 (en) 2019-06-13 2022-07-28 Lactobio A/S Gel composition comprising viable microorganisms
JP7013419B2 (ja) * 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
CN113209139B (zh) * 2020-08-31 2022-09-23 内蒙古蒙牛乳业（集团）股份有限公司 乳双歧杆菌MN-Gup改善肥胖及其特征肠道菌群用途
CN112111424B (zh) * 2020-09-03 2022-07-22 江南大学 一株可缓解类风湿性关节炎的短双歧杆菌及其应用
JP2024503366A (ja) 2021-01-05 2024-01-25 ラクトバイオ アー／エス 菌株、組成物および使用方法
US20240050493A1 (en) 2021-01-05 2024-02-15 Lactobio A/S Strains, compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1227152A1 (fr) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Souche bactérienne et genome de bifidobacterium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55113718A (en) 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
US4781939A (en) 1986-10-28 1988-11-01 Nestec, S.A. Layered meat emulsion product and method of producing same
DE3933528C1 (fr) 1989-10-04 1990-12-06 Effem Gmbh, 2810 Verden, De
US5952033A (en) 1996-12-24 1999-09-14 Nestec S.A. Gelatinized cereal product containing oligosaccharide and processes of preparing and using same
ATE206873T1 (de) 1997-01-09 2001-11-15 Nestle Sa Probiotik enthaltendes getreideprodukt
US6133323A (en) 1997-04-09 2000-10-17 The Iams Company Process for enhancing immune response in animals using β-carotene as a dietary supplement
US5932258A (en) 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
MXPA01010940A (es) 1999-05-27 2002-07-30 Iams Company Proceso y producto para mejorar la respuesta inmunitlaria en animales de compania, usando una combinacion de antioxidantes.
ATE325864T1 (de) 2000-05-25 2006-06-15 Nestle Sa Probiotica für verwendung als haustierfutter
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
ES2381211T3 (es) * 2006-02-15 2012-05-24 Nestec S.A. Uso del Bifidobacterium longum para prevenir y tratar inflamaciones
US8557233B2 (en) * 2007-03-28 2013-10-15 Alimentary Heath Limited Probiotic bifidobacterium strains
AU2008231467A1 (en) * 2007-03-28 2008-10-02 Alimentary Health Limited Probiotic Bifidobacterium strains
CA2852487C (fr) * 2008-11-11 2017-01-31 Alimentary Health Limited Souche ah1714 de bifidobacterium longum

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1227152A1 (fr) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Souche bactérienne et genome de bifidobacterium

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 19 November 2002 (2002-11-19), "Bifidobacterium longum NCC2705 related nucleotide sequence SEQ ID:1105.", retrieved from EBI accession no. GSN:ABQ81849 Database accession no. ABQ81849 *
See also references of WO2011058536A1 *

Also Published As

Publication number Publication date
CN103037875A (zh) 2013-04-10
AU2010317423B2 (en) 2014-07-10
MX2012005449A (es) 2012-09-07
PL2823822T3 (pl) 2017-09-29
CA2779597A1 (fr) 2011-05-19
AU2010317423C1 (en) 2015-01-22
RU2012116029A (ru) 2013-12-20
EP2823822B1 (fr) 2016-10-12
JP2013509204A (ja) 2013-03-14
AU2010317423A1 (en) 2012-05-31
ES2610829T3 (es) 2017-05-03
RU2557310C2 (ru) 2015-07-20
JP5600179B2 (ja) 2014-10-01
EP2823822A1 (fr) 2015-01-14
BR112012010923A2 (pt) 2018-03-06
WO2011058536A1 (fr) 2011-05-19
CA2779597C (fr) 2018-03-27
CN103037875B (zh) 2014-11-05
BR112012010923B1 (pt) 2021-03-23

Similar Documents

Publication Publication Date Title
AU2010317423C1 (en) A bifidobacterium strain
US9427000B2 (en) Feline probiotic lactobacilli composition and methods
CA2607949C (fr) Bifidobacteries de probiotiques felins
US8894991B2 (en) Canine probiotic Lactobacilli
US9259019B2 (en) Bifidobacteriumstrain
AU2011202947B2 (en) Feline probiotic lactobacilli

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120510

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140415

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALIMENTARY HEALTH LIMITED

Owner name: THE IAMS COMPANY

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE PROCTER & GAMBLE COMPANY

Owner name: ALIMENTARY HEALTH LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IAMS EUROPE B.V.

Owner name: ALIMENTARY HEALTH LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180424